Announcement • Jul 13
DarioHealth Corp. Expects Broader Deployment of DarioIQ to Increase Annual Recurring Revenue from Existing Customers DarioHealth Corp. had announced the Company expects broader deployment of DarioIQ, its proprietary, responsible generative and agentic AI platform, to increase annual Business-to-Business-to-Consumer recurring revenue by approximately 10% to 15% from existing customers, before the impact of future customer wins or additional condition expansions. DarioIQ creates an additional opportunity to lift B2B2C annual recurring revenues from current clients. By increasing member engagement, retention and clinical outcomes, DarioIQ has the potential to further boost the Company's proven return on investment of 2.5X to 5X across its programs. DarioIQ increases active member engagement by 40% and improved member retention by 20% through highly personalized interventions tailored to each member's unique health profile and behavior, as compared to the control group. These results reflect DarioIQ development completed in the first half of 2026, and the Company expects performance to continue improving as the models are enhanced with additional data. Unlike general-purpose AI models trained primarily on public information, DarioIQ is powered by a de-identified dataset of more than 13 billion proprietary real-world healthcare data points collected across Dario's business-to-consumer experience. By combining biometric readings from U.S. Food and Drug Administration-cleared connected devices, clinical history and member behavioral engagement patterns, DarioIQ determines the right message, delivered through the right channel, at the right time for each individual member. This helps improve engagement while increasing the efficiency of outreach. Every new member interaction strengthens the intelligence of the system, further enhancing the asset as the platform grows and AI capabilities continue to evolve. Consistent with Dario's responsible-AI practices, DarioIQ operates with human and clinical oversight, privacy safeguards and continuous monitoring. The Company's recently announced expansion into provider-backed care further increases the long-term value of DarioIQ by connecting AI-driven engagement directly to clinical intervention. As Dario expands into larger healthcare markets, the same AI engine can support a broader range of clinical workflows, provider interactions and reimbursement opportunities. Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution. Announcement • Jul 11
DarioHealth Corp. Announces Extension of Medical Leave Of Absence of Steven Nelson, President and Chief Commercial Officer, for Indefinite Period DarioHealth Corp. announced that on July 10, 2026, the temporary medical leave of absence of Steven Nelson, President and Chief Commercial Officer was extended for an indefinite period. During Mr. Nelson’s leave of absence, his responsibilities are being assumed by members of the Company’s senior management team. Live News • Jul 03
Top 5 U.S. Health Insurer Expands DarioHealth Partnership to Cardiometabolic Care DarioHealth announced that a top 5 U.S. health insurer has extended its agreement for mental health services and added Dario’s hypertension solution, expanding into cardiometabolic care and potentially tripling the company’s revenue opportunity with this customer.
The insurer is now DarioHealth’s third health plan client to broaden its relationship beyond an initial condition, which supports the company’s multi-condition platform and “land and expand” approach by increasing the addressable population under existing contracts.
DarioHealth shares trade at $7.27, with the stock down 30.9% year to date, so this contract expansion arrives against a backdrop of recent share price pressure.
This kind of contract deepening can matter more than winning entirely new logos, since it shows existing customers are finding enough value to roll out DarioHealth across more conditions. The main risk is execution on scaling outcomes and utilization to match the larger opportunity. Announcement • Jun 30
DarioHealth Corp. Announces Appointment of Sean O'reilly to Advisory Board DarioHealth Corp. announced the appointment of Sean O'Reilly to its Advisory Board. Mr. O'Reilly brought extensive healthcare compliance, risk management, regulatory oversight and legal experience across complex healthcare, insurance and clinical operations. He had led compliance programs supporting Medicare Advantage, Medicaid, employer group medical and specialty insurance, military healthcare, hospice and home health, value-based primary care and pharmacy benefit management organizations. Prior to consulting in a prominent Healthcare Risk Management & Advisory practice, O'Reilly spent more than 13 years at Humana, including serving as Senior Vice President and Chief Compliance Officer, where he led enterprise compliance programs across Medicare Advantage, Medicaid, employer-sponsored health plans, pharmacy benefit management, home health, hospice, military healthcare and value-based care operations. His experience leveraging advanced data analytics and AI to strengthen compliance oversight, operational performance and value-based care aligned closely with Dario's commitment to delivering measurable healthcare outcomes through innovative technology solutions. Mr. O'Reilly was also a licensed attorney with a background in mergers and acquisitions. His work integrated privacy, ethics and technology-driven risk analysis to strengthen compliance culture, support operational integrity and enable strategic growth. Announcement • Jun 09
Dariohealth Corp Presents Four Studies At American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of Its Digital Health Platform DarioHealth Corp. presented four studies at the American Diabetes Association's Scientific Sessions highlighting the clinical and economic value of sustained engagement on its platform across high-risk cardiometabolic populations. Data from a total of 27 studies presented at ADA over 8 years reinforce Dario's strategic move closer to care, expanding revenue model into claims-based and outcomes-driven payments serving health plans, employers and other enterprise buyers. Weight loss of 6.4% with Dario alone, and 14.3% when combined with a GLP-1 at 12 months, exceeding benchmarks based on medications alone. 44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction at 12 months. Across the four studies, Dario observed meaningful reductions in inpatient utilization among high-risk members with diabetes, hypertension and obesity, strong weight outcomes with and without GLP-1 therapy, improved glycemic control and a clear link between consistent engagement and better results. The findings support Dario's core enterprise thesis: sustained engagement in a single cardiometabolic digital platform can produce measurable clinical improvement across overlapping chronic conditions, while reducing avoidable utilization and the cost and complexity of managing multiple point solutions. The growing body of data including 27 studies presented at the ADA alone over the past eight years supports Dario's next strategic growth phase moving closer to care--demonstrating the platform's impact on clinical outcomes and positioning the Company to participate in the medical spend associated with those outcomes. Among the findings, when compared with the control group, participants experienced 0.23 fewer hospitalizations per patient per year (PPPY), highlighting Dario's potential to reduce acute healthcare utilization. In a prior Dario study, similar improvements were associated with estimated payer savings of approximately $5,077 per participant per year. Additional data showed that Dario's digital health intervention alone delivered 6.4% weight loss at 12 months, while combining Dario with GLP-1 therapy produced 14.3% weight loss, exceeding real-world pharmacotherapy-only benchmarks. Dario also found that 44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction at 12 months, while consistent engagement predicted both weight loss and glycemic improvement. The four presentations further underscore Dario's platform approach to cardiometabolic care. Dario's core capabilities include its AI-driven engagement engine, connected devices and personalized human coaching, which together are designed to support sustained behavior change across diabetes, hypertension and weight management. Strategic highlights include: High-risk population impact: Demonstrated inpatient-utilization improvement in members with diabetes, hypertension and obesity. Economic relevance: Findings support the potential for avoided admission costs and broader payer savings. Weight-management performance: Strong 12-month weight outcomes both as a standalone digital intervention and in combination with GLP-1 therapy. Engagement differentiation: Consistent engagement predicted stronger clinical outcomes, reinforcing Dario's platform design and long-term habit-building model. Cardiometabolic breadth: Evidence of value across multiple related conditions and outcome categories within a single platform. Reported Earnings • May 14
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: US$1.25 loss per share. Revenue: US$5.58m (down 17% from 1Q 2025). Net loss: US$8.25m (loss widened 21% from 1Q 2025). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Breakeven Date Change • May 13
Forecast to breakeven in 2028 The 3 analysts covering DarioHealth expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 34% per year to 2027. The company is expected to make a profit of US$500.0k in 2028. Average annual earnings growth of 64% is required to achieve expected profit on schedule. Announcement • May 04
DarioHealth Corp. to Report Q1, 2026 Results on May 13, 2026 DarioHealth Corp. announced that they will report Q1, 2026 results Pre-Market on May 13, 2026 Announcement • Apr 21
DarioHealth Corp. Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program DarioHealth Corp. announced the publication of new peer-reviewed research in JMIR Formative Research demonstrating meaningful improvements in workplace functioning among participants using Dario's digital behavioral health program. The study, titled Enhancing Workplace Outcomes Through Digital Behavioral Health Programs: Retrospective Real–World Study, demonstrated statistically significant improvements in workplace functioning among users of Dario's behavioral health solutions. Among 1,254 users who reported concentration difficulties at baseline, significant improvements were observed within the first six weeks, with even greater gains by weeks 6 to 10. Comparable improvements were observed for procrastination (n=1,004) and mistakes at work (n=167). These measures – focus, task completion and accuracy – are established contributors to absenteeism and presenteeism. For employers and health plans, the findings reinforce the connection between behavioral health and workforce productivity – an increasingly significant driver of both employee well-being and total cost of care. For employers, the stakes are significant: illness-related lost productivity – including absenteeism and reduced on-the-job performance (i.e., presenteeism) – costs U.S. employers an estimated $575 billion annually. This highlights the need for scalable solutions like Dario that help employees manage health challenges while maintaining daily functioning at work. The publication adds to the growing body of peer-reviewed evidence supporting Dario's digital health platform, which integrates behavioral health with cardiometabolic support to address the interconnected chronic condition management needs of employer and health plan populations. Announcement • Apr 14
DarioHealth Corp. Appoints John R. Palumbo to Board of Directors DarioHealth Corp. announced the appointment of John R. Palumbo to its Board of Directors. Mr. Palumbo brings more than 40 years of healthcare operating experience across early-stage ventures and Fortune 100 enterprises. His substantial background includes senior leadership roles at AmerisourceBergen Corporation (now Cencora Inc.), where he led the provider business unit and expanded consulting and technology capabilities into a multibillion-dollar platform serving health systems nationwide, as well as Chief Operating Officer of Allscripts Healthcare Solutions Inc. (now Veradigm Inc.) and leadership positions at Shared Medical Systems Corporation (Siemens Aktiengesellschaft). Mr. Palumbo has guided organizations through transformative growth, including supporting two companies through IPOs and leading large-scale operational and commercial transformations. His experience is particularly relevant to Dario's evolution toward a more capital-efficient, partner-led go-to-market strategy. He brings deep familiarity with the care delivery ecosystem, including the health systems, payers and provider services organizations that are shaping its consolidation – adding a dimension of strategic reach that directly complements Dario's next phase. In addition to his operating capabilities, Mr. Palumbo is actively engaged in the digital health ecosystem. He currently serves on the boards of PM Pediatrics Management Group, LLC, Lucid Diagnostics Inc., ivWatch, LLC and Qless Inc., and chairs the advisory board of Brado Cuneo Nollau, LLC, an AI-driven engagement platform serving health systems. Announcement • Mar 31
DarioHealth Corp. has filed a Follow-on Equity Offering in the amount of $20 million. DarioHealth Corp. has filed a Follow-on Equity Offering in the amount of $20 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Major Estimate Revision • Mar 26
Consensus estimates of losses per share improve by 56% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from US$25.8m to US$26.4m. EPS estimate increased from -US$9.67 per share to -US$4.30 per share. Healthcare Services industry in the US expected to see average net income growth of 22% next year. Consensus price target up from US$18.00 to US$18.80. Share price rose 2.9% to US$8.48 over the past week. Reported Earnings • Mar 19
Full year 2025 earnings released: US$10.47 loss per share (vs US$12.27 loss in FY 2024) Full year 2025 results: US$10.47 loss per share. Revenue: US$22.4m (down 17% from FY 2024). Net loss: US$41.7m (loss widened 39% from FY 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Price Target Changed • Mar 17
Price target increased by 9.6% to US$20.00 Up from US$18.25, the current price target is an average from 5 analysts. New target price is 129% above last closing price of US$8.75. Stock is down 36% over the past year. The company is forecast to post a net loss per share of US$15.18 next year compared to a net loss per share of US$12.27 last year. Announcement • Mar 11
DarioHealth Corp. to Report Q4, 2025 Results on Mar 19, 2026 DarioHealth Corp. announced that they will report Q4, 2025 results Pre-Market on Mar 19, 2026 Announcement • Mar 10
DarioHealth Corp. Announces Publication of New Peer-Reviewed Research in Frontiers in Digital Health Demonstrating Substantial and Sustained Blood Glucose Improvements Among Users of the Dario Platform DarioHealth Corp. announced the publication of new peer-reviewed research in Frontiers in Digital Health demonstrating substantial and sustained blood glucose improvements among users of the Dario platform. The observational study, titled "Machine learning and engagement insights for personalized blood glucose management," analyzed real-world data from 22,414 adults with type 2 diabetes and baseline blood glucose levels in the high-risk range. Using advanced machine learning models and longitudinal mixed-effects analyses, researchers identified distinct glycemic trajectories moderated by demographic, clinical and engagement factors. By applying generalized linear mixed-effects tree models, researchers uncovered key moderating factors that influence glycemic improvement. Outcomes suggested broad across diverse user populations, as demonstrated with no meaningful body mass index difference across ethnicities. Higher levels of digital engagement – specifically frequent blood glucose monitoring and lifestyle activities tags – were associated with stronger, more durable glycemic improvements. A key, actionable insight identified 12 measurements per month as a threshold of glycemic improvement. The analysis further reveals specific frequency of measurements that drive clinical outcomes and bend the cost curve. The published findings underscore Dario's ability to translate real-world data into measurable clinical impact for clients. Announcement • Mar 03
DarioHealth Corp. Announces Oral GLP-1 Digital Health Solution With Precision Behavioral Support DarioHealth Corp. announced increasing employer and health plan demand for its oral GLP-1 digital health solution, which is purpose-built to strengthen medication impact through precision behavioral support at scale. As oral GLP-1 therapies enter the market, data suggest they deliver slightly more modest weight and glycemic outcomes compared to injectable formulations. That dynamic elevates the importance of the surrounding behavioral infrastructure. Success ultimately depends on daily execution – timing, fasting windows, food decisions, symptom management and persistence through adjustment periods. Dario's book of business data shows that 79% of members engage in weight management within its integrated multi-condition platform. As a result, the Company has an extensive population benefiting from the solution's structured reinforcement. Dario's deep experience and data around weight management is a critical asset, as GLP-1 medication spending remains one of the fastest-growing cost drivers for payers – with oral GLP-1s expected to capture 25% of the overall GLP-1 market, projected to reach $95 billion by 2030, according to Goldman Sachs. Rather than layering generic education around therapy, Dario embeds precision behavioral tools directly into the treatment journey. Key capabilities include: Medication cabinet to support adherence tracking and reduce dose-timing drift; Grocery scanner to translate weight-loss intent into smarter real-world food decisions; Access to a personal human coach to reinforce habit formation and persistence. Together, these features create a tightly paired intervention model – aligning pharmacotherapy with real-time awareness to reinforce sustained behavior change. As the use of oral GLP1's expands beyond specialty care into primary care and employer populations, scale introduces new challenges in monitoring adherence, managing early side effects and preventing premature discontinuation. Without structured behavioral support, modest efficacy combined with inconsistent habits can erode long-term value. Major Estimate Revision • Jan 07
Consensus EPS estimates fall by 10% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$13.78 to -US$15.18 per share. Revenue forecast unchanged at US$22.3m. Healthcare Services industry in the US expected to see average net income growth of 29% next year. Consensus price target of US$18.25 unchanged from last update. Share price rose 26% to US$13.48 over the past week. Announcement • Dec 16
DarioHealth Corp., Annual General Meeting, Jan 29, 2026 DarioHealth Corp., Annual General Meeting, Jan 29, 2026. Location: 5 tarshish st., 2nd floor, caesarea industrial park, 3088900., Israel Announcement • Dec 11
Dario Launches DarioIQ AI Integration in Dario Health App with Direct-To-Consumer First Version for Hypertension Members DarioHealth Corp. announced the launch of the Dario Health app enhanced with DarioIQ, the Company's new artificial intelligence ("AI") layer, delivered as a direct-to-consumer first version for an initial cohort of hypertension members who enrolled to access the new experience. This launch marks the first major milestone in Dario's multi-phase introduction of conversational AI designed to enhance, not replace, the human-centered guidance central to chronic condition management. The introduction of DarioIQ adds a clinically aligned, conversational layer that operates side-by-side with Dario's data and experience-driven mobile application. The system integrates behavioral insights, real-time biometric interpretation and personalised guidance, supported by seamless medical-device connectivity and Dario's existing human coaching framework. This deployment represents a foundational step in Dario's evolution GenAI roadmap, with patient safety at the forefront. Dario began with a direct-to-consumer hypertension support to anchor DarioIQ in a high-impact condition area while refining the integrated conversational experience, before expanding across the full suite of Dario solutions for employers and health plans. This phase will inform expansion across diabetes, weight management, behavioral health, musculoskeletal conditions and additional chronic pathways. Members in the initial cohort opted in specifically to use the enhanced experience, ensuring transparency and maintaining trust in the company's introduction of DarioIQ. Dario selected its direct-to-consumer marketspace to refine user interactions and evaluate safety and performance within a controlled, mature ecosystem. This approach allows Dario to bring a fully validated, evidence-supported AI capability to its business-to-business ("B2B") partners - avoiding risks associated with unproven or hypothetical generative models. Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit . Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements iwhen it discusses that the Company expects that the Company expects that its GenAI roadmap will enable a seamless conversational AI experience across the platform; that the introduction of DarioIQ represents a major moment for Dario; the future expansion of DarioIQ across additional chronic conditions; that the GenAI experience is expected to power the next generation of the Company's platform; that by launching a direct-to-consumer version, it expects that it will be able to learn from real engagement, ensure safety and clinical alignment, and deliver a mature, evidence-based capability to its employer and payer collaborations; and the future benefits of the Company's platform. Announcement • Dec 04
Dariohealth Corp. Announces Publication of A New Peer-Reviewed Study in JMIR Cardio Demonstrating That Data-Driven Nodges Delivers Significant and Sustainable Improvements in Blood Pressure Outcomes DarioHealth Corp. announced publication of a new peer-reviewed study in JMIR Cardio demonstrating that data-driven nudges delivered via Dario's digital health platform are associated with significant and sustainable improvements in blood pressure ("BP") outcomes. The study, titled "The Impact of Digital Intervention Messages Targeting Users With High Blood Pressure Events: Retrospective Real-World Study," analyzed real-world BP data from platform users whose health was tracked over time, comparing a cohort that received digital intervention messages to a propensity-matched control group. According to the CDC, nearly 120 million people in the U.S. live with hypertension, a major public health challenge that has been identified as the leading preventable risk factor for premature death. 59% of Dario's clients leverage its cardio-metabolic suite to support members in managing hypertension. Key findings were that among users with high BP (high-BP cohort), those receiving digital nudges experienced a statistically significant reduction in monthly average systolic blood pressure three months after the intervention (B =2.09; P <.001), compared to a smaller reduction in the control group (B = -1.06; P =.007). Users reporting higher lifestyle activity levels further achieved greater systolic blood pressure reduction (B =-5.27; P <.001), underscoring the additive benefit of behavioral engagement in conjunction with digital nudges. This research provides important real-world clinical evidence that personalized, data-driven digital interventions can meaningfully reduce blood pressure in individuals with hypertension - and help maintain healthy BP levels in individuals without overt hypertension. The fact that BP improvements persisted over time after the initial intervention shows that digital nudges via Dario's platform are not merely momentary triggers, but instead can support sustained, long-term management of hypertension. Reported Earnings • Nov 16
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: US$6.01 loss per share (further deteriorated from US$4.91 loss in 3Q 2024). Revenue: US$5.01m (down 33% from 3Q 2024). Net loss: US$18.9m (loss widened 90% from 3Q 2024). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 32%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. New Risk • Nov 16
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$27m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$27m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (297% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Market cap is less than US$100m (US$79.4m market cap). Announcement • Nov 06
DarioHealth Corp. to Report Q3, 2025 Results on Nov 13, 2025 DarioHealth Corp. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 13, 2025 Major Estimate Revision • Sep 29
Consensus EPS estimates fall by 13% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$19.53 to -US$22.00 per share. Revenue forecast of US$23.9m unchanged since last update. Healthcare Services industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$25.50 to US$22.25. Share price rose 71% to US$13.27 over the past week. New Risk • Sep 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$16m net loss in 3 years). Market cap is less than US$100m (US$23.0m market cap). Announcement • Sep 25
DarioHealth Corp. announced that it has received $17.500011 million in funding On September 25, 2025, DarioHealth Corp closed the transaction. Announcement • Sep 22
DarioHealth Corp. announced that it expects to receive $17.500011 million in funding DarioHealth Corp. announced a private placement of 2,713,180 shares of common stock at a price of $6.45 per share for expected aggregate gross proceeds of $1,75,00,011 on September 22, 2025. The closing of the offering is expected to occur on or about September 23, 2025, subject to the satisfaction of customary closing conditions. New Risk • Aug 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$27m free cash flow). Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$16m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$19.7m market cap). Major Estimate Revision • Aug 19
Consensus revenue estimates fall by 25% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$32.1m to US$24.2m. Forecast losses increased from -US$0.83 to -US$0.977 per share. Healthcare Services industry in the US expected to see average net income growth of 22% next year. Consensus price target down from US$2.38 to US$1.96. Share price rose 2.7% to US$0.44 over the past week. Price Target Changed • Aug 13
Price target decreased by 17% to US$1.96 Down from US$2.38, the current price target is an average from 4 analysts. New target price is 336% above last closing price of US$0.45. Stock is down 51% over the past year. The company is forecast to post a net loss per share of US$0.98 next year compared to a net loss per share of US$0.61 last year. Reported Earnings • Aug 13
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2025 results: US$0.37 loss per share (further deteriorated from US$0.085 loss in 2Q 2024). Revenue: US$5.37m (down 14% from 2Q 2024). Net loss: US$18.6m (loss widened 451% from 2Q 2024). Revenue missed analyst estimates by 22%. Earnings per share (EPS) exceeded analyst estimates by 23%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings. Announcement • Aug 05
DarioHealth Corp. to Report Q2, 2025 Results on Aug 12, 2025 DarioHealth Corp. announced that they will report Q2, 2025 results at 9:30 AM, US Eastern Standard Time on Aug 12, 2025 Announcement • Jul 11
DarioHealth Corp. Appoints Steven M. Nelson as President, Effective July 10, 2025 On July 10, 2025, DarioHealth Corp. appointed Steven M. Nelson, 52, the Company’s current Chief Commercial Officer, as both its President and Chief Commercial Officer, effective July 10, 2025. Mr. Nelson has served as the Company’s Chief Commercial Officer since June 5, 2024. From October 2018 to September 2023, he served as President and Chief Executive Officer of Contigo Health, a Premier Inc. subsidiary. Prior to that, Mr. Nelson held several leadership roles at Anthem Inc. (now Elevance Health), including Chief Operating Officer of its diversified services business—now known as Carelon—from 2017 to 2018; Vice President of Strategy, Planning & Innovation from 2015 to 2016; and Chief of Staff to the Chief Financial Officer from 2016 to 2017. From 2007 to 2014, he served as Senior Vice President of Strategy, Product & Marketing at Highmark Inc., and concurrently as Senior Vice President of Executive Oversight at Allegheny Health Network from 2012 to 2014, a wholly owned subsidiary of Highmark. Earlier in his career, Mr. Nelson held senior roles in the consumer health and marketing sectors, including Senior Vice President at GNC Holdings, LLC; General Manager of Brand Marketing and Promotions for MET-Rx Nutrition Inc.; Vice President of International Marketing for 141 Communicator; and Director of Marketing & Omnicom Integration at GMR Marketing LLC. Mr. Nelson holds a Bachelor of Science in Education from the University of Pittsburgh at Johnstown and a Master of Arts in Business Administration from Ohio University. Announcement • Jun 24
DarioHealth Corp. Unveils GLP-1 and AI-Personalization Digital Health Findings DarioHealth Corp. announced four new studies presented this past weekend at the 85th Annual American Diabetes Association ("ADA") Scientific Sessions in Chicago. The research, which represents Dario's 25th published study at the ADA's Scientific Sessions over the last decade, includes findings in sustaining GLP-1 weight loss and artificial intelligence ("AI")-powered personalization that highlight the Company's platform's critical contribution in the digital health market. Key highlights from the research include a dramatic eA1c reduction from 9.0% to 6.7% in GLP-1 users, with users seeing sustained results for six (6) months after medication discontinuation, and AI predictive accuracy of 89% for future glucose levels, demonstrating Dario's unique position to deliver value in the GLP-1 market where payers and employers seek solutions that maximize their investment in these costly medications. The Company is currently leveraging these findings in ongoing implementations and commercial discussions with payers and self-insured employers seeking integrated solutions for chronic condition management, particularly around GLP-1 optimization programs. The first study examined 715 GLP-1 users and revealed significant clinical improvements for those engaging with Dario's platform. Most importantly, the research showed that users who discontinued GLP-1 medication maintained stable outcomes, reflecting no significant weight or glucose rebound, for at least six (6) months, addressing a critical industry challenge where patients typically experience rebound effects after stopping treatment. Key study results included: Among continued GLP-1 users with elevated glucose levels, average blood glucose dropped from an eA1c of 9.0%. Digital lifestyle engagement activities significantly enhanced outcomes with meal and physical activity logging associated with stronger blood glucose improvements. Three additional studies published at the ADA conference offer insights on the potential of AI and real-world data to drive more personalized, effective chronic condition management. The studies reflect early research fueling Dario's next-generation AI platform, which leverages machine learning to tailor interventions based on real-time behaviors, clinical biomarkers, and user demographics. Key results from the studies include: 89% accuracy in predicting next-month blood glucose levels using a machine learning model informed by user behavior and activity--not just clinical data. Machine learning revealed that the first four months of engagement and consistent self-care behaviors are key opportunities to apply AI for more personalized, adaptive diabetes care to improve outcomes. New Risk • May 23
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 0.8% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (47% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$36m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$31.6m market cap). Announcement • May 22
DarioHealth Corp., Annual General Meeting, Jul 23, 2025 DarioHealth Corp., Annual General Meeting, Jul 23, 2025. Location: 5 tarshish st., 2nd floor, caesarea industrial park, 3088900, Israel Major Estimate Revision • May 21
Consensus EPS estimates fall by 149% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$0.333 to -US$0.83 per share. Revenue forecast unchanged at US$32.1m. Healthcare Services industry in the US expected to see average net income growth of 28% next year. Consensus price target broadly unchanged at US$2.38. Share price rose 4.6% to US$0.69 over the past week. Reported Earnings • May 16
First quarter 2025 earnings: EPS and revenues miss analyst expectations First quarter 2025 results: US$0.30 loss per share (further deteriorated from US$0.20 loss in 1Q 2024). Revenue: US$6.75m (up 17% from 1Q 2024). Net loss: US$14.1m (loss widened 103% from 1Q 2024). Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings. Announcement • May 08
DarioHealth Corp. Announces New Research Published in the Journal of Medical Internet Research DarioHealth Corp. announced new research published in the Journal of Medical Internet Research ("JMIR") demonstrating the effectiveness of personalized digital health interventions to drive flu vaccination awareness in Dario members living with diabetes. People living with diabetes are at risk of severe complications from the flu, yet low awareness keeps many from receiving an influenza vaccination. To better understand how digital health tools could raise awareness and improve vaccination rates in this population a pragmatic randomized follow-up study was performed using Dario's digital health solution for diabetes management which delivers a highly personalized, whole health approach to help members improve overall health and outcomes. The study also aimed to highlight the effectiveness of personalizing digital interventions to positively impact member engagement and behavior change. A previous randomized controlled study ("RCT") proved the effectiveness of a nudge intervention to improve vaccination rates, and Dario's study's was designed as a pragmatic follow-up to translate the initial insights into a real-world setting. To accomplish this, the research team leveraged Dario's capabilities around personalization to deliver tailored messaging across a large data set of 64,904 members segmented into three groups: first, a group of members with exposure to a monthly flu vaccination campaign previously proven to impact vaccination rates; second, a group of members receiving an adapted version of the same campaign with more personalized and frequent messages; and third, a control group with no exposure to flu vaccination messages. The results showcase the power of personalized digital health interventions with the second group demonstrating significantly improved awareness of the risks associated with the flu and higher rates of vaccination than the group receiving the messages previously tested in the RCT. By helping members better understand their health and take action, such as avoiding severe flu-related complications, the company believe that Dario is able to improve both individual well-being and client outcomes. Announcement • May 07
DarioHealth Corp. to Report Q1, 2025 Results on May 14, 2025 DarioHealth Corp. announced that they will report Q1, 2025 results on May 14, 2025 Announcement • May 02
DarioHealth Corp. announced that it has received $32.5 million in funding from Rand Capital LLC, Callodine Group, LLC DarioHealth Corp. announced that it has raised $32.5 million in debt round of funding on May 1, 2025. The transaction included participation from new lenders, Rand Capital LLC, Callodine Group, LLC. The has issued a warrant to purchase 2,114,140 shares of common stock, with an exercise price of $0.8278. In addition, up to $2.5 million of the loaned amount can be converted into shares of the Company's common stock at a price of $0.9933 per share. Announcement • Mar 20
Nasdaq Grants Extension of 180 Days to DarioHealth to Regain Compliance with Minimum Bid Price Requirement As previously disclosed, on September 16, 2024, DarioHealth Corp., received a written notification (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was granted 180 calendar days, or until March 17, 2025, to regain compliance with the Minimum Bid Price Requirement. On March 18, 2025, the Company received a letter (the “Letter”), from the Staff approving an extension of an additional 180 calendar days from the date of the Letter, or until September 15, 2025 (the “Additional Compliance Period”) to regain compliance with the Minimum Bid Price Requirement. The Company’s Common Stock will continue to trade under the symbol “DRIO.” If at any time during the Additional Compliance Period, the bid price of the Common Stock closes at or above $1.00 per share for a minimum of ten (10) consecutive trading days, Nasdaq will provide the Company with written confirmation of compliance with the Minimum Bid Price Requirement and the matter will be closed. If the Company does not regain compliance within the Additional Compliance Period or does not comply with the terms of the extension, Nasdaq will provide notice that the Company’s securities will be delisted from The Nasdaq Capital Market. The Company intends to continuously monitor the closing bid price for its Common Stock and is in the process of considering various measures to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement, including a stock split, if necessary. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement, even if it maintains compliance with the other Nasdaq listing requirements. Reported Earnings • Mar 10
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: US$0.84 loss per share (improved from US$1.93 loss in FY 2023). Revenue: US$27.0m (up 33% from FY 2023). Net loss: US$41.0m (loss narrowed 25% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 46%. Revenue is expected to decline by 5.0% p.a. on average during the next 3 years, while revenues in the Healthcare Services industry in the US are expected to grow by 9.7%. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Announcement • Mar 04
DarioHealth Corp. to Report Q4, 2024 Results on Mar 10, 2025 DarioHealth Corp. announced that they will report Q4, 2024 results Pre-Market on Mar 10, 2025 Announcement • Mar 01
DarioHealth Corp. Announces Board Changes DarioHealth Corp. announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure, 74, has extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and value-based care models, will be instrumental in guiding Dario's continued expansion within the payer and employer markets. Mr. Leisure began his professional career in benefits consulting ultimately serving as National Practice Leader at Towers Perrin (aka Willis Towers Watson) then transitioning to management consulting first as a Senior Partner at PricewaterhouseCoopers and later as a Managing Partner at Accenture. He went on to serve in senior leadership roles at Kaiser Foundation Health Plan and UnitedHealth Group's OptumInsight unit. His pivot to health care investing started with his joining the venture capital firm of Kleiner Perkins as an Operating Partner. In 2014, he co-founded Chicago Pacific Founders, a health care focused private equity firm. As an ardent advocate for innovation in healthcare, Mr. Leisure co-founded the Employer Health Innovation Roundtable, a coalition representing over six million lives. Mr. Leisure is Chairman of the UCSF Rosenman Institute, member of the UCLA Anderson School of Management Board of Advisors, and a Senior Advisor at the Mussalem Center for BIODESIGN at Stanford University. He received his BA in Economics from Stanford University and his MBA in Finance from the UCLA Anderson School of Management. He resides in Atherton, California with his wife, Bren. Mr. Leisure is also a Member of NearWater Growth, LLC, or NearWater, which has provided investment and business consulting services to the Company since 2021 pursuant to a consulting agreement, as amended, by and between the Company and NearWater effective as of September 3, 2021, or the Consulting Agreement. On February 24, 2025, Jon Kaplan voluntarily resigned from his position as a member of the Board. Mr. Kaplan did not resign as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Board Change • Feb 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Member of Advisory Board Allen Kamer was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. New Risk • Jan 23
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$25m net loss in 3 years). Market cap is less than US$100m (US$28.8m market cap). New Risk • Jan 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (26% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$25m net loss in 3 years). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (US$29.1m market cap). Announcement • Dec 19
DarioHealth Corp. announced that it has received $18.805 million in funding On December 18, 2024. DarioHealth Corp. has closed transaction. Reported Earnings • Nov 08
Third quarter 2024 earnings: EPS exceeds analyst expectations Third quarter 2024 results: US$0.30 loss per share (improved from US$0.49 loss in 3Q 2023). Revenue: US$7.42m (up 111% from 3Q 2023). Net loss: US$12.3m (loss narrowed 13% from 3Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 8.5%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. Announcement • Oct 25
DarioHealth Corp., Annual General Meeting, Dec 18, 2024 DarioHealth Corp., Annual General Meeting, Dec 18, 2024. Location: 5 tarshish st. caesarea industrial park 3088900, 2nd floor, Israel Announcement • Oct 23
DarioHealth Corp. to Report Q3, 2024 Results on Nov 07, 2024 DarioHealth Corp. announced that they will report Q3, 2024 results Pre-Market on Nov 07, 2024 Announcement • Sep 21
DarioHealth Corp. Receives A Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement On September 16, 2024, DarioHealth Corp. (the Company") received a written notice from the Nasdaq Stock Market LLC (Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid price for its common stock was below $1.00 per share for the last 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until March 17, 2025, to regain compliance with the minimum bid price requirement. During the compliance period, the Company's common stock will continue to be listed and traded on the Nasdaq Stock Market. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period. If the Company is not in compliance by March 17, 2025, the Company may be afforded a second 180-calendar day compliance period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq with the exception of the minimum bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company intends to monitor the closing bid price of its common stock between now and March 17, 2025, and will consider available options to resolve the Company's noncompliance with the minimum bid price requirement as may be necessary. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria. Price Target Changed • Aug 27
Price target decreased by 21% to US$3.83 Down from US$4.83, the current price target is an average from 3 analysts. New target price is 351% above last closing price of US$0.85. Stock is down 73% over the past year. The company is forecast to post a net loss per share of US$1.09 next year compared to a net loss per share of US$1.93 last year. Major Estimate Revision • Aug 18
Consensus revenue estimates decrease by 18%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$33.9m to US$27.7m. EPS estimate increased from -US$1.64 to -US$1.09 per share. Healthcare Services industry in the US expected to see average net income growth of 23% next year. Consensus price target of US$4.83 unchanged from last update. Share price rose 12% to US$0.88 over the past week. Major Estimate Revision • Aug 15
Consensus revenue estimates decrease by 21%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$33.9m to US$26.7m. EPS estimate increased from -US$1.64 to -US$1.21 per share. Healthcare Services industry in the US expected to see average net income growth of 24% next year. Consensus price target of US$5.50 unchanged from last update. Share price was steady at US$0.91 over the past week. New Risk • Aug 12
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 4.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.5% per year for the foreseeable future. Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$41m). Currently unprofitable and not forecast to become profitable over next 3 years (US$45m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (US$23.7m market cap). Reported Earnings • Aug 09
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2024 results: US$0.34 loss per share (improved from US$0.58 loss in 2Q 2023). Revenue: US$6.26m (up 1.7% from 2Q 2023). Net loss: US$13.6m (loss narrowed 17% from 2Q 2023). Revenue missed analyst estimates by 21%. Earnings per share (EPS) exceeded analyst estimates by 86%. Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. Announcement • Jul 30
DarioHealth Corp. to Report Q2, 2024 Results on Aug 08, 2024 DarioHealth Corp. announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024 Major Estimate Revision • Jun 16
Consensus EPS estimates fall by 11%, revenue upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$31.4m to US$33.9m. Forecast EPS reduced from -US$1.48 to -US$1.64 per share. Healthcare Services industry in the US expected to see average net income growth of 25% next year. Consensus price target of US$5.67 unchanged from last update. Share price fell 11% to US$1.16 over the past week. Announcement • Jun 06
DarioHealth Corp. Announces Management Changes DarioHealth Corp. announced a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitability. To achieve this goal, DarioHealth is transitioning to a flatter organizational model. The President role will be eliminated, and dedicated C-level positions will be established for each core function, reporting directly to the Chief Executive Officer. The newly created role of Chief Commercial Officer (CCO) will be in addition to the existing C-Level roles in the Company. The Company believes that this structure fosters a more collaborative environment and ensures clear lines of communication which are essential for driving successful commercialization initiatives. Further strengthening its commercial focus, DarioHealth is excited to announce the appointment of Steven Nelson as its Chief Commercial Officer of DarioHealth, Mr. Nelson will be instrumental in developing and executing strategies to drive rapid commercialization. Mr. Nelson will oversee Dario's global commercial activities, including growth strategy, sales, client management, marketing, strategic partnerships, and expansion into new markets. Mr. Nelson brings over two decades of experience building and scaling technology-centric healthcare companies. Most recently, Mr. Nelson served as the Chief Executive Officer and President of Contigo Health, a multi-faceted collaborator for healthcare providers, plans and employers. During his tenure at Contigo Health, he led the company to revenue scale and turned the business to profitability, managed over 75 clients in the portfolio, and established several national and regional health plan partnerships as well as employer relationships. Before his role at Contigo, Nelson served as the Chief Operating Officer of Anthem Inc.'s Diversified Business Group. There, he played a pivotal role in the "One Anthem" transformation initiative that developed strategic business plans resulting in a $7 billion run-rate revenue. In a mutual agreement, Rick Anderson will step down in his role as President of the Company and will join the advisory board of DarioHealth. New Risk • May 17
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$39m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$39m). Currently unprofitable and not forecast to become profitable over next 3 years (US$19m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (US$55.8m market cap). 
